New drug combo shows promise for rare bone marrow failure

NCT ID NCT02099747

Completed Disease control Sponsor: European Society for Blood and Marrow Transplantation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding eltrombopag to standard immunosuppressive therapy improves early recovery in patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. 202 participants received either standard treatment (horse antithymocyte globulin plus cyclosporine) or the same treatment plus eltrombopag. The main goal was to see if more patients achieved a complete blood count response within three months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE APLASTIC ANEMIA

Contacts and locations

Locations

'Federico II' Medical School

Naples, Italy
AMC

Amsterdam, Netherlands
AOU Città della Salute e della Scienza di Torino

Turin, Italy
Azienda Ospedaliera Papa Giovanni XXIII

Bergamo, Italy
Centre Hospitalier Lyon-Sud

Lyon, France
City Hospital

Nottingham, United Kingdom
Donostia Hospital

Donostia / San Sebastian, Spain
Fondazione IRCCS ca Granda Ospedale

Milan, Italy
Hopital Jean Minjoz

Besançon, France
Hospital La Fe

Valencia, Spain
Hospital Universitari Germans Trias I Pujol

Badalona, Spain
Hôpital Haut-Lévèque

Bordeaux, France
Hôpital Huriez

Lille, France
Hôpital Purpan

Toulouse, France
Institut Català d'Oncologia - Hospital Duran i Reynals

Barcelona, Spain
Istituto G. Gaslini children's Hospital

Genova, Italy
King's College Hospital

London, United Kingdom
La Sapienza University Hospital

Rome, Italy
Leiden University Medical Center

Leiden, Netherlands
Pontchaillou Hospital

Rennes, France
San Martino Hospital

Genova, Italy
St. Bartholomew's Hospital

London, United Kingdom
St. James Hospital

Leeds, United Kingdom
St. Louis Hospital

Paris, France
UMCG

Groningen, Netherlands
UMCU

Utrecht, Netherlands
University Hospital Basel

Basel, Switzerland
University Hospital Bern

Bern, Switzerland
University Hospital Zürich

Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.